Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

Type
Private
HQ
Utrecht, NL
Founded
2003
Size (employees)
86 (est)+3%
Website
merus.nl
Merus was founded in 2003 and is headquartered in Utrecht, NL
Report incorrect company information

Key People/Management at Merus

L. Sirulnik

L. Sirulnik

EVP & Chief Medical Officer
Mark Throsby

Mark Throsby

EVP & Chief Scientific Officer
Lex Bakker

Lex Bakker

SVP & Chief Development Officer
John Crowley

John Crowley

EVP & Chief Financial Officer
John de Kruif

John de Kruif

SVP & Chief Technology Officer
Hui Liu

Hui Liu

EVP & Chief Business Officer
Show more

Merus Office Locations

Merus has an office in Utrecht
Utrecht, NL (HQ)
62 Yalelaan
Utrecht, NL (HQ)
H.R. Kruytgebouw 8 Padualaan
Show all (2)
Report incorrect company information

Merus Financials and Metrics

Summary Metrics

Merus's latest funding round in April 2015 was reported to be $79.1 m. In total, Merus has raised $149.3 m
Show all financial metrics
Report incorrect company information